AQST News

Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

ARDT DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ardent Health (ARDT) Investors of Securities Class Action Deadline on March 9, 2026 Ready to Announce with Confidence?

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics Ready to Announce with Confidence?

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation

Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics Ready to Announce with Confidence?

Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Shareholders to Inquire about Securities Investigation